Dr. Alexander Wyatt is a senior research scientist with the Vancouver Prostate Centre and an assistant professor with an academic focus on cancer genomics. He has a broad background in basic molecular biology and genetics, as well as eight years of experience in cancer bioinformatics and the analysis of complex datasets. His primary research goals are to dissect the clinical relevance of genomic alterations in metastatic genitourinary cancers, and develop minimally-invasive biomarkers for guiding therapy selection.
Dr. Wyatt's lab leverages a variety of innovative next-generation sequencing techniques to interrogate tissue and liquid biopsies from patients enrolled on a series of ongoing clinical trials and protocols. His lab also works very closely with Dr. Kim Chi and other senior medical oncologists and urologists, and together they have recently demonstrated that plasma circulating tumor DNA (ctDNA) is highly representative of metastatic lesions in prostate and bladder cancer, and that somatic alterations detected in ctDNA can help predict therapy resistance or response.